Antifungal Activity of Turkish Honey against Candida spp. and Trichosporon spp: An in vitro evaluation

Medical Mycology

Volumn 47, Issue 7, 2009, Pages 707-712

  Koc, Ayşe Nedret ^a   Silici, Sibel ^a   Ercal, Bariş Derya ^a   Kasap, Filiz ^a   Hörmet Z, Hatice Tuna ^a   Mavus Buldu, Hikmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Antifungal activity; Candida spp.; Fluconazole; Honey; Trichosporon spp.

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CONCENTRATION RESPONSE; EUCALYPTUS; FUNGUS GROWTH; GROWTH INHIBITION; HONEY; IN VITRO STUDY; NONHUMAN; RHODODENDRON; TRICHOSPORON;

ANTIFUNGAL AGENTS; CANDIDA; FLUCONAZOLE; HONEY; MICROBIAL SENSITIVITY TESTS; TRICHOSPORON; TURKEY;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; EUCALYPTUS; RHODODENDRON;

EID: 71049165631     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780802572554     Document Type: Article

References (35)

1. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989; 8: 323-330.
2. Anaissie E, Bodey P. Disseminated trichosporonosis: meeting the challenge. Eur J Clin Microbiol Infect Dis 1991; 10: 711-713.
3. Cawley MJ, Braxon GR, Haith LR, et al. Trichosporon beigelii infection: experience in a regional burn center. Burns 2000; 26: 483-486.
4. Espinel-Ingroff A. Comparison in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743, 872) and LY 303366 against opportunistic fi lamenteus and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
5. Hoy J, Hsu KC, Rolston K, et al. Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8: 959-967.
6. Trick WE, Fridkin SK, Edwards JR, Hejjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System Hospitals: Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
7. Pfaller MA, Diekema DJ, Jones RN, et al. SENTRY participant group: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
8. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. NEMIS study Group: National Epidomiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
9. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-478.
10. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 2004; 48: 101-105.
11. Kirkpatrick WR, Revankar SG, McAtee RK, et al. Detection of Candida dubliniensis in oropharyngeal samples from humanimmunodefi ciency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998; 36: 3007-3012.
12. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14: 161-169.
13. White TC, Marr KA, Bowden RA. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
14. Cameron ML, Schell WA, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodefi ciency cirus type 1. Antimicrob Agents Chemother 1993; 37: 2449-2453.
15. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro- in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on antifungal Susceptibility Testing of the national Committee for Clinical Laboratory standards. Clin Infect Dis 1997; 24: 235-247.
16. Molan PC. The antibacterial activity of honey: 2. Variation in the potency of the antibacterial activity. Bee World 1992; 73: 59-76.
17. Weston RJ, Mitchell KR, Allen KL. Antibacterial phenolic components of New Zealand manuka honey. Food Chem 1999; 64: 295-301.
18. Lusby PE, Coombes AL, Wilkinson JM. Bactericidal activity of different honeys against pathogenic bacteria. Arch Med Res 2005; 36: 464-467.
19. Finola MS, Lasagno MC, Marioli JM. Microbial and chemical characterization of honeys from central Argentina. Food Chem 2007; 100: 1649-1653.
20. Sissons CH, Anderson SA, Molan PC, Suppression of C. albicans in plaque microcosms by manuka honey. IADR/AADR/CADR 82nd General Session in Honolulu, Hawai,2004.
21. Boukraa L, Benbarek H, Moussa A. Synergistic action of starch and honey against C. albicans in correlation with diastase number. Braz J Microbiol 2008; 39: 40-43.
22. Al-Waili NS. Mixture of honey, beeswax and olive oil inhibits growth of Staphylococcus aureus and C. albicans. Arch Med Res 2005; 36: 10-13.
23. Irish J, Carter DA, Shokohi T, Blair SE. Honey has an antifungal effect against Candida species. Med Mycol 2006; 44: 289-291.
24. Louveaux J, Maurizio A, Vorwohl G. Methods of melissopalynology. Bee World 1978; 59: 139-157.
25. Pendleton M. Descriptions of melissoplaynological methods involving centrifugation should include data for calculating Relative Centrifugal Force (RCF) or should express data in units of RCF or gravites (g). Grana 2006; 45: 71-72.
26. Waren NG, Hazen NC. Candida,Cryptococcus and other yeast of medical importance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology,1995; 723-737.
27. National Committee for Clinical Laboratory Standards. R eference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard NCCLS document M27-A2. Wayne, PA : National Committee for Clinical Laboratory Standards,2002.
28. MINITAB 2000. MINITAB Statistical Software,Release 13.20, Minitab Inc. State College, PA, USA.
29. Al-Waili N. Therapeutic and prophylactic effects of crude honey on chronic seborrheic dermatitis and dandruff. Eur J Med Res 2001; 6: 306-308.
30. Obaseiki-Ebor EE, Afonya TC. In vitro evaluation of the anticandiasis activity of honey distillate (HY-1) compared with that of some antimycotic agents. J Pharm Pharmacol 1984; 36: 283-284.
31. Gil M, Ferreres F, Ortiz A, Subra E, Tomas-Barberan FA. Plant phenolic metabolites and fl oral origin of rosemary honey. J Agric Food Chem 1995; 43: 2833-2838.
32. Kucuk M, Kolayli S, Karaoglu S, et al. Biological activities and chemical composition of three honeys of different types from Anatolia. Food Chem 2007; 100: 526-534.
33. Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Ag 2005; 26: 343-356.
34. Andrade P, Ferreres F, Gil MI, Tomas-Barberan FA. Determination of phenolic compounds in honeys with different floral origin by capillary zone electrophoresis. Food Chem 1997; 60: 79-84.
35. Allen KL. The potential for using honey to treat wounds infected with MRSA and VRE, First World Healing Congress, 12-13 September, Melbourne, Australia,2000.